Preventive and / or therapeutic agents for aneurysms

A P2X4 receptor inhibitor-based drug addresses the need for drug therapies by inhibiting inflammatory markers to prevent and treat cerebral aneurysms, providing a safer and more effective alternative to surgical interventions.

JP7577440B2Active Publication Date: 2024-11-05福田 俊一
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2019196606
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2019-10-29
Publication Date
2024-11-05
Estimated Expiration
2039-10-29

AI Technical Summary

Technical Problem

Current treatments for cerebral aneurysms are limited to surgical interventions, and there is a lack of effective drug therapies to prevent or treat aneurysms, particularly for unruptured ones, with existing drugs like statins showing minimal efficacy and potential side effects.

Method used

A prophylactic and therapeutic agent containing a P2X4 receptor inhibitor, such as paroxetine, is used to inhibit inflammatory markers and suppress aneurysm growth by targeting vascular endothelial cells, reducing the expression of COX-2, TNF-α, MCP-1, iNOS, and IL-1β.

Benefits of technology

The agent effectively reduces the inner diameter of unruptured aneurysms and prevents recurrence or re-enlargement by suppressing inflammatory responses and vascular remodeling, offering a safer alternative to surgical methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007577440000002
    Figure 0007577440000002
  • Figure 0007577440000003
    Figure 0007577440000003
  • Figure 0007577440000001
    Figure 0007577440000001
Patent Text Reader

Abstract

To provide an aneurysm prophylactic and / or therapeutic agent.SOLUTION: An aneurysm prophylactic and / or therapeutic agent has a P2X4 receptor inhibitor as an active ingredient. The P2X4 receptor inhibitor is paroxetine. Thus, it is possible to prevent increase of cerebral aneurysm with respect to cases of unruptured cerebral aneurysm, and also to prevent relapses after cerebral aneurysm coil embolization. Administering of the P2X4 receptor inhibitor, such as paroxetine, reduces expression of aneurysm-associated factors such as COX-2, TNF-α, MCP-1, iNOS, IL-1β.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a preventive and / or therapeutic agent for aneurysm, specifically, a preventive and / or therapeutic agent for cerebral aneurysm. [Background technology]

[0002] Cerebral aneurysms are lesions that occur at the bifurcation of cerebral blood vessels, and are an important disease as they are the main cause of fatal subarachnoid hemorrhage. In order to prevent subarachnoid hemorrhage, it is necessary to treat the rupture of unruptured cerebral aneurysms, which are often found in daily clinical practice.

[0003] The rupture rate of cerebral aneurysms varies depending on their size and location, and it has been reported that the larger they are, the more likely they are to rupture, and that aneurysms that show a tendency to grow have a higher rupture rate. The only treatments available for unruptured cerebral aneurysms are surgical treatments such as craniotomy for clipping or catheter-based coil embolization.

[0004] At present, there is no drug therapy for cerebral aneurysms, so many cases go untreated. In light of this situation, it is necessary to clarify the mechanisms of cerebral aneurysm formation, growth, and rupture, and to develop new drug therapies based on this knowledge. If the growth of aneurysms can be suppressed, it is expected that the rupture rate will be reduced. In addition, it has been reported that approximately 15-30% of cerebral aneurysm cases treated with coil embolization recur and grow again, and the development of preventive drugs is awaited.

[0005] However, the clinical usefulness of statin drugs for cerebral aneurysms has not been shown to be significant, and since most patients with cerebral aneurysms are not dyslipidemic, when administering statin drugs to non-dyslipidemic patients, it is a prerequisite that safety and the risk of inducing hypocholesterolemia are adequately guaranteed.

[0006] Recent analyses using a series of model animals have demonstrated that the formation and growth of cerebral aneurysms are controlled by an inflammatory response induced by blood flow stress, which was previously thought to be the cause of cerebral aneurysms. Therefore, cerebral aneurysms can be defined as a chronic inflammatory disease of the cerebral vascular wall that is dependent on blood flow stress.

[0007] Hemodynamics plays an important role in the development and growth of cerebral aneurysms, and it is believed that the detection of excessive hemodynamic load in cerebral blood vessels by vascular endothelial cells triggers a series of events that lead to the development and growth of cerebral aneurysms (Non-patent literature 1, 2). [Prior art documents] [Non-patent literature]

[0008] [Non-Patent Document 1] Multivariate analysis of hemodynamic risk factors for rupture of cerebral aneurysms, Shunichi Fukuda, Proceedings of the 30th Bioengineering Conference of the Japan Society of Mechanical Engineers, December 2017 [Non-Patent Document 2] The role of hemodynamic factors in the formation, growth, and rupture of cerebral aneurysms: A study using complementary computational fluid dynamics (CFD) analysis and animal model experiments, Shunichi Fukuda, Journal of Neurosurgery, 2014, Vol. 23, No. 8 Summary of the Invention [Problem to be solved by the invention]

[0009] The present invention has been made in view of the above problems, and an object of the present invention is to provide a drug capable of preventing and / or treating aneurysms. [Means for solving the problem]

[0010] The preventive and / or therapeutic drug for aneurysm according to the present invention is characterized by having a P2X4 receptor inhibitor as an active ingredient. Effect of the Invention

[0011] According to the present invention, aneurysms can be appropriately prevented and / or treated. [Brief description of the drawings]

[0012] [Figure 1]FIG. 1 shows a comparison of the mRNA expression levels of (A) COX-2, (B) TNF-α, (C) MCP-1, (D) IL-1β, and (E) iNOS in experimentally induced cerebral aneurysms in rats by RT-PCR analysis. [Diagram 2] FIG. 1 shows a comparison of the protein expression levels of (A) COX-2, (B) TNF-α, (C) MCP-1, (D) IL-1β, and (E) iNOS in experimentally induced cerebral aneurysms in rats by Western blotting analysis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] Hereinafter, an embodiment of the present invention will be described in detail with reference to the attached drawings. However, the embodiment is intended to facilitate understanding of the principles of the present invention, and the scope of the present invention is not limited to the embodiment described below. Other embodiments in which a person skilled in the art appropriately replaces the configuration of the embodiment described below are also included in the scope of the present invention.

[0014] The preventive and / or therapeutic drug for aneurysm according to the present invention contains a P2X4 receptor inhibitor as an active ingredient.

[0015] P2X receptors are nonselective cation channels, and their structure is such that two-pass transmembrane subunits (approximately 400-600 amino acid residues) assemble to form an ion channel. P2X4 receptors have higher calcium permeability than other P2X receptors. In humans, P2X4 receptors are expressed in a wide range of organs, including the brain, spinal cord, heart, lungs, liver, and kidneys. Although they are distributed intracellularly, they are characterized by being localized in lysosomes, but are spared from proteolysis due to multiple sugar chains on the P2X4 receptors on the lysosomal lumen side. P2X4 receptors expressed in vascular endothelial cells are involved in vascular remodeling induced by vasodilatory responses and changes in blood flow.

[0016] The inhibitor of P2X4 receptor is an antagonist against P2X4 receptor. For example, the antagonist against P2X4 receptor includes selective serotonin reuptake inhibitor (SSRI), specifically, paroxetine, fluoxetine, fluvoxamine, citalopram, etc., preferably paroxetine. Paroxetine has been used as an antidepressant under the trade name Paxil, and has been shown to have no significant side effects, so that it is expected to be clinically applied as a preventive and / or therapeutic drug against the growth of unruptured cerebral aneurysm and recurrence and re-growth after coil embolization. Coil embolization of unruptured cerebral aneurysm is a method of filling the cerebral aneurysm with a platinum coil to occlude the aneurysm, and is called coil embolization (endovascular surgery).

[0017] The aneurysm is not particularly limited, and examples thereof include abdominal aortic aneurysm, thoracic aortic aneurysm, cerebral aneurysm, etc., but is preferably cerebral aneurysm. The shape of the cerebral aneurysm is, for example, saccular or fusiform. The most common type is saccular cerebral aneurysm, with small ones having an inner diameter of 1-2 mm and large ones having an inner diameter of more than 20-30 mm.

[0018] In this specification, "treatment" includes curing symptoms, improving symptoms, and suppressing the progression of symptoms. In the case of an unruptured aneurysm, there are almost no symptoms and there is only a risk of rupture until the lump presses on a nerve, but in this specification, both the case where an unruptured aneurysm presses on a nerve and the potential case where there is a risk of rupture without pressing on a nerve are included in the "symptoms". Specifically, it includes eliminating an unruptured aneurysm and suppressing the growth of an unruptured aneurysm. Suppressing the growth of an unruptured aneurysm includes reducing the inner diameter of an unruptured aneurysm and suppressing the increase in the inner diameter of an unruptured aneurysm (i.e., maintaining the current inner diameter of an unruptured aneurysm where the increase in the inner diameter is expected). On the other hand, "prevention" includes suppressing and delaying the onset of a disease, and includes not only prevention before the onset of a disease, but also prevention against the recurrence of a disease after treatment. Specifically, it includes suppressing and delaying the onset of an aneurysm, and includes prevention of recurrence after coil embolization of a cerebral aneurysm.

[0019] Cerebral aneurysms can be defined as a chronic inflammatory disease of the cerebral vascular wall dependent on blood flow stress, and there is a relationship between the formation of cerebral aneurysms and inflammatory markers. Leukocyte migration and adhesion factors involved in cerebral vascular wall damage, such as P-selectin, E-selectin, cellular adhesion molecula-leukocyte-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and P-selectin glyroprtein ligand 1 (PSGL-1), as well as inflammation-related molecules such as MMP-9, are thought to be involved in the development and growth of cerebral aneurysms.

[0020] Macrophages are the cell type responsible for the inflammatory response in the walls of cerebral blood vessels, and NF-κB activation and the COX-2-PGE2-EP2 pathway have been identified as factors responsible for the response. Therefore, inhibiting COX-2 may suppress the pathology of cerebral aneurysms.

[0021] In addition, the inflammation-related factor TNF-α and the macrophage migration factor MCP-1 are also involved in the development of cerebral aneurysms, and inhibiting these factors may make it possible to suppress the pathology of cerebral aneurysms.

[0022] In addition, induced nitric oxide synthase (iNOS), a type of NO synthesis enzyme, is expressed in cerebral aneurysms, and inhibition of iNOS gene expression can suppress the pathology of cerebral aneurysms.

[0023] It has been confirmed that procollagen protein expression is reduced in the wall of cerebral aneurysms from the early stage of their formation, and the cytokine IL-1β significantly reduces procollagen gene expression in a dose-dependent manner. Therefore, inhibition of IL-1β expression can suppress the pathology of cerebral aneurysms.

[0024] As shown in the Examples below, according to the present invention, the expression of aneurysm-related factors such as COX-2, TNF-α, MCP-1, iNOS, and IL-1β can be reduced by administering a P2X4 receptor inhibitor such as paroxetine, thereby suppressing the growth of cerebral aneurysms, for example.

[0025] The preventive and / or therapeutic drug for aneurysm according to the present invention contains a P2X4 receptor inhibitor as an active ingredient, and may also contain additives generally used in pharmaceuticals.

[0026] Examples of additives include excipients, binders, lubricants, disintegrants, colorants, flavorings, emulsifiers, surfactants, solubilizers, suspending agents, isotonicity agents, buffers, preservatives, antioxidants, stabilizers, and absorption enhancers. These can also be used in appropriate combinations, if desired.

[0027] Specifically, the excipients include, for example, lactose, sucrose, glucose, corn starch, mannitol, sorbitol, starch, alpha-starch, dextrin, crystalline cellulose, light anhydrous silicic acid, aluminum silicate, calcium silicate, magnesium aluminometasilicate, calcium hydrogen phosphate, etc. The binders include, for example, polyvinyl alcohol, methylcellulose, ethylcellulose, gum arabic, tragacanth, gelatin, shellac, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone, macrogol, etc. The lubricants include, for example, magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, polyethylene glycol, colloidal silica, etc. The disintegrants include, for example, crystalline cellulose, agar, gelatin, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, low-substituted hydroxypropylcellulose, carboxymethylcellulose, calcium carboxymethylcellulose, croscarmellose sodium, carboxymethylstarch, sodium carboxymethylstarch, etc. Examples of the coloring agent include ferric oxide, yellow ferric oxide, carmine, caramel, β-carotene, titanium oxide, talc, sodium riboflavin phosphate, yellow aluminum lake, and other additives permitted for use in pharmaceuticals. Examples of the flavoring agent include cocoa powder, peppermint, aromatic powder, peppermint oil, menthol, borneol, and cinnamon powder. Examples of the emulsifier or surfactant include stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, glycerin monostearate, sucrose fatty acid ester, and glycerin fatty acid ester. Examples of the solubilizing agent include polyethylene glycol, propylene glycol, benzyl benzoate, ethanol, cholesterol, triethanolamine, sodium carbonate, sodium citrate, polysorbate 80, and nicotinamide.Examples of the suspending agent include, in addition to the surfactants, hydrophilic polymers such as polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylcellulose. Examples of the isotonicity agent include glucose, sodium chloride, mannitol, and sorbitol. Examples of the buffer include buffer solutions such as phosphates, acetates, carbonates, and citrates. Examples of the preservatives include methylparaben, propylparaben, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, and sorbic acid. Examples of the antioxidants include sulfites, ascorbic acid, and α-tocopherol. Examples of the stabilizers include ascorbic acid, sodium edetate, erythorbic acid, and tocopherol. Examples of the absorption promoters include isopropyl myristate, tocopherol, and calciferol.

[0028] The dosage of the preventive and / or therapeutic agent for aneurysm according to the present invention can be appropriately set within a range in which the P2X4 receptor inhibitor as an active ingredient does not show toxicity to the recipient. For example, the optimal amount can be appropriately determined depending on the physique, age, sex, etc. of the recipient, and the degree of symptoms, etc. The same applies to the administration interval and number of times. Although not particularly limited, for example, it can be 0.01 to 1,000 mg per adult per day. Specifically, it can be 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 250, or 500 mg. It is preferably 10 to 40 mg per day. EXAMPLES

[0029] (1) Verification of the reduction of cerebral aneurysms Rats with cerebral aneurysm induction were prepared. Seven-week-old Sprague-Dawley rats were purchased, and after intraperitoneal injection of sodium pentobarbital (40 mg / kg), the left carotid artery and left renal artery were ligated with 10-0 nylon thread. After surgery, the rats were fed a special diet containing 8% sodium chloride and 0.2% BAPN. The initial changes in cerebral aneurysm were confirmed by the following procedure. After intraperitoneal injection of sodium pentobarbital (40 mg / kg), the chest was opened to expose the heart, a 23G butterfly needle was placed in the left ventricle from the apex, and the brain was perfused with 4% paraformaldehyde. The brain was removed, soaked in 4% paraformaldehyde overnight, and the cerebral blood vessels were removed, serial frozen sections were prepared, and the cerebral blood vessels were observed under a microscope.

[0030] Next, when paroxetine was administered to the rats with cerebral aneurysm induction for 3 weeks, the inner diameter of the cerebral aneurysm was significantly reduced compared to the non-administered group (Table 1). The inner diameter of human cerebral aneurysm can be measured by MRA, 3D-CTA, 3D-DSA, etc., or by calibrating with a disk or coin of known size during DSA imaging. In this example, the maximum diameter of the rat cerebral aneurysm was measured by observing serial frozen sections under a microscope. When paroxetine was administered to rats for 1 week 2 weeks after the cerebral aneurysm induction operation, the maximum diameter was significantly smaller than that of the non-administered group (Table 1). Note that aneurysms had already developed in all rats 2 weeks after the cerebral aneurysm induction operation. This proves that unruptured cerebral aneurysms can be reduced by administering paroxetine for 1 week, and therefore paroxetine is useful as a treatment and / or preventive agent for unruptured cerebral aneurysms.

[0031] [Table 1]

[0032] (2) Verification of factors related to cerebral aneurysms The expression levels of various inflammatory factors (MCP-1, IL1s, TNFα, iNOS, and COX-2) that have been reported to be related to the growth of cerebral aneurysms were examined by PCR and Western blotting. Figure 1 shows a comparison of the mRNA expression levels of (A) COX-2, (B) TNF-α, (C) MCP-1, (D) IL-1β, and (E) iNOS in experimentally induced cerebral aneurysms in rats by RT-PCR analysis. Figure 2 shows a comparison of the protein expression levels of (A) COX-2, (B) TNF-α, (C) MCP-1, (D) IL-1β, and (E) iNOS in experimentally induced cerebral aneurysms in rats by Western blotting analysis. Compared to the non-operated rat group, the protein and mRNA expression of all inflammatory factors was significantly increased in the cerebral aneurysm-inducing surgery group, and furthermore, administration of paroxetine to the surgical group significantly reduced the expression of all these inflammatory factors (Figures 1 and 2). [Industrial Applicability]

[0033] It can be used to prevent and / or treat cerebral aneurysms.

Claims

1. The active ingredient is an inhibitor of the P2X4 receptor, which is expressed in the endothelial cells of blood vessels in unruptured cerebral aneurysms that have already developed. the P2X4 receptor inhibitor is paroxetine; A therapeutic drug for cerebral aneurysms, characterized in that it inhibits the growth of cerebral aneurysms in cases of unruptured cerebral aneurysms.

2. The therapeutic agent for cerebral aneurysm according to claim 1, characterized in that the cerebral aneurysm is saccular or fusiform.

3. 3. The therapeutic agent for cerebral aneurysm according to claim 1 or 2, which prevents recurrence of cerebral aneurysm after coil embolization.